Cargando…

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center

Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes the switching process at a National Cancer Institute...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piezzo, Michela, D’Aniello, Roberta, Avallone, Ilaria, Barba, Bruno, Cianniello, Daniela, Cocco, Stefania, D’Avino, Antonio, Di Gioia, Germira, Di Lauro, Vincenzo, Fusco, Giuseppina, Piscitelli, Raffaele, von Arx, Claudia, De Laurentiis, Michelino, Maiolino, Piera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151152/ https://www.ncbi.nlm.nih.gov/pubmed/34068626 http://dx.doi.org/10.3390/pharmaceutics13050684

Ejemplares similares

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
por: Cocco, Stefania, et al.
Publicado: (2020)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Piezzo, Michela, et al.
Publicado: (2020)

Targeting Autophagy in Breast Cancer
por: Cocco, Stefania, et al.
Publicado: (2020)

Male Breast Cancer: From Molecular Genetics to Clinical Management
por: Pensabene, Matilde, et al.
Publicado: (2022)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
por: López-Morales, Carlos A., et al.
Publicado: (2015)

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
por: Cocco, Stefania, et al.
Publicado: (2022)

Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
por: Jassem, Shea, et al.
Publicado: (2019)

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
por: Botti, Gerardo, et al.
Publicado: (2017)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))
por: Hurst, Susan, et al.
Publicado: (2014)

Can we establish a hierarchy among trastuzumab biosimilar candidates?
por: Pivot, Xavier, et al.
Publicado: (2018)

Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
por: Paek, Kyungyeol, et al.
Publicado: (2019)

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
por: Triantafyllidi, Eleni, et al.
Publicado: (2022)

A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results
por: Cozzolino, Mauro, et al.
Publicado: (2021)

Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
por: Barat, Eric C., et al.
Publicado: (2023)

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
por: Riccio, Gennaro, et al.
Publicado: (2018)

Clinical trials and drug cost savings for Italian health service
por: D’Ambrosio, Francesca, et al.
Publicado: (2020)

A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
por: Zhou, Xinna, et al.
Publicado: (2015)

In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
por: Chen, Liuxi, et al.
Publicado: (2016)

Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
por: Hutterer, Katariina M., et al.
Publicado: (2019)

Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars
por: Azuz, Samuel, et al.
Publicado: (2021)

Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2015)

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017)

Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
por: Moghimi, Minoosh, et al.
Publicado: (2021)

Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
por: Kolberg, Hans-Christian, et al.
Publicado: (2021)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
por: Barszczewska, Olga, et al.
Publicado: (2021)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
por: Yang, Charlie, et al.
Publicado: (2022)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
por: Facchini, Gaetano, et al.
Publicado: (2016)

Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
por: Cecere, Sabrina C., et al.
Publicado: (2016)

Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
por: Cecere, Sabrina C., et al.
Publicado: (2016)

Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial
por: Morita, Jun, et al.
Publicado: (2015)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ananpc0gd299oaeglq1um265oq